[go: up one dir, main page]

UY27208A1 - Una combinación que comprende combretastatina y agentes anticarcinógenos. - Google Patents

Una combinación que comprende combretastatina y agentes anticarcinógenos.

Info

Publication number
UY27208A1
UY27208A1 UY27208A UY27208A UY27208A1 UY 27208 A1 UY27208 A1 UY 27208A1 UY 27208 A UY27208 A UY 27208A UY 27208 A UY27208 A UY 27208A UY 27208 A1 UY27208 A1 UY 27208A1
Authority
UY
Uruguay
Prior art keywords
anticarcinogen
combination
agents
combretastatine
epidophilotoxins
Prior art date
Application number
UY27208A
Other languages
English (en)
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of UY27208A1 publication Critical patent/UY27208A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se provee una combinación antitumoral que comprende un derivado del estilbeno y un compuesto anticarcinógeno seleccionado entre el grupo consistente en taxanos, agentes alquilantes, antimetabolitos, alcaloides de la vinca, epidófilotoxinas y antibióticos como componentes activos. También se proveen métodos para utilizar estas preparaciones farmacéuticas para el tratamiento de carcinomas sólidos y similares.
UY27208A 2001-03-15 2002-03-14 Una combinación que comprende combretastatina y agentes anticarcinógenos. UY27208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27562701P 2001-03-15 2001-03-15

Publications (1)

Publication Number Publication Date
UY27208A1 true UY27208A1 (es) 2002-08-30

Family

ID=23053164

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27208A UY27208A1 (es) 2001-03-15 2002-03-14 Una combinación que comprende combretastatina y agentes anticarcinógenos.

Country Status (37)

Country Link
US (4) US20020183266A1 (es)
EP (1) EP1439839B8 (es)
JP (1) JP4991107B2 (es)
KR (1) KR100849610B1 (es)
CN (2) CN1290504C (es)
AR (1) AR032989A1 (es)
AT (1) ATE433750T1 (es)
AU (1) AU2002304574B2 (es)
BR (1) BR0208017A (es)
CA (2) CA2673449C (es)
CY (1) CY1109364T1 (es)
CZ (1) CZ302451B6 (es)
DE (1) DE60232673D1 (es)
DK (1) DK1439839T3 (es)
EA (1) EA006316B1 (es)
EC (1) ECSP034766A (es)
ES (1) ES2327617T3 (es)
HR (1) HRPK20030734B3 (es)
HU (1) HU228510B1 (es)
IL (2) IL157891A0 (es)
MA (1) MA27000A1 (es)
ME (2) MEP16208A (es)
MX (1) MXPA03007552A (es)
NO (1) NO332661B1 (es)
NZ (1) NZ527526A (es)
PE (1) PE20020909A1 (es)
PL (1) PL205728B1 (es)
PT (1) PT1439839E (es)
RS (1) RS50682B (es)
SI (1) SI1439839T1 (es)
SK (1) SK287908B6 (es)
TN (1) TNSN03060A1 (es)
TW (1) TWI306028B (es)
UA (1) UA75127C2 (es)
UY (1) UY27208A1 (es)
WO (2) WO2002074229A2 (es)
ZA (1) ZA200306789B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69931766T2 (de) * 1998-04-03 2007-05-31 Ajinomoto Co., Inc. Antitumorale mittel
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
GB0410817D0 (en) * 2004-05-14 2004-06-16 Angiogene Pharm Ltd Vascular damaging therapy
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN1319978C (zh) * 2005-04-06 2007-06-06 西南合成制药股份有限公司 康布瑞汀化合物的制备方法
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US20080104512A1 (en) * 2006-10-31 2008-05-01 Motorola, Inc. Method and apparatus for providing realtime feedback in a voice dialog system
WO2009067706A1 (en) * 2007-11-21 2009-05-28 Oxigene, Inc. Method for treating hematopoietic neoplasms
US20090209496A1 (en) * 2008-02-15 2009-08-20 David Chaplin Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2939665B1 (fr) * 2008-12-12 2011-10-07 Sanofi Aventis Combinaison antitumorale associant l'ave8062a et le docetaxel
FR2945210B1 (fr) * 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib
EP2397135A1 (en) 2010-06-18 2011-12-21 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
MX2012014732A (es) 2010-06-18 2013-01-22 Sanofi Sa Una combinacion antitumoral que comprende ombrabulina un derivado de taxano y un derivado de platino.
EP2481404A1 (en) 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2407161A1 (en) 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
FR2968557A1 (fr) 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
JP2018523712A (ja) 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
US9980953B2 (en) * 2016-09-26 2018-05-29 Chong Kun Dang Pharmaceutical Corp. Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5731353A (en) * 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) * 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) * 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
DE69931766T2 (de) * 1998-04-03 2007-05-31 Ajinomoto Co., Inc. Antitumorale mittel
US6242770B1 (en) * 1998-08-31 2001-06-05 Gary Bela Bronner Diode connected to a magnetic tunnel junction and self aligned with a metallic conductor and method for forming the same
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
SK5122003A3 (en) * 2000-10-27 2003-12-02 Aventis Pharma Sa A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
CA2432792C (en) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US6466448B1 (en) * 2001-06-11 2002-10-15 Network Appliance, Inc. Riser board retaining and air ducting structure for printed circuit boards

Also Published As

Publication number Publication date
IL157891A0 (en) 2004-03-28
CN1547471A (zh) 2004-11-17
EA200301015A1 (ru) 2004-08-26
CZ302451B6 (cs) 2011-05-25
CZ20032476A3 (en) 2004-07-14
ME00056B (me) 2010-06-10
CA2673449C (en) 2011-10-18
MXPA03007552A (es) 2004-10-15
EA006316B1 (ru) 2005-10-27
NO332661B1 (no) 2012-11-26
AR032989A1 (es) 2003-12-03
CN1290504C (zh) 2006-12-20
CA2470484A1 (en) 2004-05-06
MEP16208A (en) 2010-06-10
CA2470484C (en) 2009-10-13
HRPK20030734B3 (en) 2006-11-30
ES2327617T3 (es) 2009-11-02
US20030060429A1 (en) 2003-03-27
UA75127C2 (en) 2006-03-15
JP2005522527A (ja) 2005-07-28
US20020183266A1 (en) 2002-12-05
HU228510B1 (en) 2013-03-28
NZ527526A (en) 2006-11-30
HRP20030734A2 (en) 2005-06-30
AU2002304574A1 (en) 2004-05-13
KR100849610B1 (ko) 2008-07-31
AU2002304574B2 (en) 2005-09-15
TNSN03060A1 (en) 2005-12-23
SK11552003A3 (sk) 2004-03-02
YU71303A (sh) 2006-08-17
DK1439839T3 (da) 2009-10-05
CN1935134A (zh) 2007-03-28
WO2002074229A2 (en) 2002-09-26
DE60232673D1 (de) 2009-07-30
US20070149476A1 (en) 2007-06-28
SK287908B6 (sk) 2012-03-02
US20050075295A1 (en) 2005-04-07
PL205728B1 (pl) 2010-05-31
RS50682B (sr) 2010-06-30
EP1439839B1 (en) 2009-06-17
HUP0600233A2 (en) 2008-06-30
EP1439839A1 (en) 2004-07-28
EP1439839B8 (en) 2010-09-01
HK1067039A1 (en) 2005-04-01
PE20020909A1 (es) 2002-12-09
CN1935134B (zh) 2010-12-15
IL157891A (en) 2010-06-16
ECSP034766A (es) 2003-10-28
CA2673449A1 (en) 2004-05-06
ATE433750T1 (de) 2009-07-15
WO2004037258A1 (en) 2004-05-06
SI1439839T1 (sl) 2011-09-30
ZA200306789B (en) 2005-02-23
PL374406A1 (en) 2005-10-17
TWI306028B (en) 2009-02-11
MA27000A1 (fr) 2004-12-20
BR0208017A (pt) 2004-12-07
PT1439839E (pt) 2009-09-03
NO20034022D0 (no) 2003-09-11
CY1109364T1 (el) 2014-07-02
NO20034022L (no) 2003-09-11
HUP0600233A3 (en) 2010-03-29
KR20040067866A (ko) 2004-07-30
JP4991107B2 (ja) 2012-08-01
US6933320B2 (en) 2005-08-23

Similar Documents

Publication Publication Date Title
UY27208A1 (es) Una combinación que comprende combretastatina y agentes anticarcinógenos.
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
ES2112880T3 (es) Inhibidores de la proteasa de vih utiles para el tratamiento del sida.
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
UY26130A1 (es) Compuestos para tratar la obesidad
PE20020348A1 (es) Exemestano como agente quimiopreventivo
UY27886A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco.
DK0934065T3 (da) Hidtil ukendte cruptophycinderivater som antieoplastiske midler
ATE405568T1 (de) Cytotoxische mittel
PA8527401A1 (es) 7-oxo-piridopirimidinas (ii)
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
AR027677A1 (es) Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer
CR6513A (es) Polimorfos de un citrato de azobiciclo 2,2,2, oct-3-ilamina cristalino y sus composiciones farmeceuticas
AR005730A1 (es) Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato.
ES2168240T3 (es) Uso de inhibidores de aceticolina-esterasa para tratar delirios.
AR027037A1 (es) Compusto y metodo para el tratamiento del dolor
GT200100099A (es) Derivados de higromicina a.
DE60303131D1 (de) Synergistische wechselwirkung von abacavir und alovudin
AR036257A1 (es) Sulfamatos de 2-alcoxiestradiol de accion antitumoral

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141126